Novosteo Inc.
Fracture-targeted anabolic therapeutic administered via subcutaneous injection, designed to selectively accumulate on bone fracture sites and accelerate healing
- Sector
- Biotech
- Headquarters
- West Lafayette, IN
- Founded
- 2017
- Latest Form D
- $4.3M, Jan 2021
- Total capital
- $8.1M
- Federal grants
- $3.8M
- 4 awards · 2018–2020
- Rank in peer group#94 of 326
- Private capital raised
- $4.3M
- 1 Form D · last Jan 2021
- 69 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.3M
- Federal grantHealth and Human S · Phase II · Targeting Therapeutics for Accelerated Bone Fracture Repair$1.3M
- Federal grantHealth and Human S · Phase II · Targeting Therapeutics for Accelerated Bone Fracture Repair$1.8M
- Federal grantHealth and Human S · Phase II · Targeting Therapeutics for Accelerated Bone Fracture Repair$547K
- Federal grantHealth and Human S · Phase II · Targeting Therapeutics for Accelerated Bone Fracture Repair$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
28months
from Novosteo Inc.’s first federal award to its first private round.
- First federal award · Sep 2018
- Health and Human S · $225K
- First Form D · Jan 2021
- $4.3M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#94 · top 29%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alex S. AndrianopoulosDirectorNamed in SEC Form D filings
- Dan S. HaslerDirectorNamed in SEC Form D filings
- Daniel S. HaslerDirectorNamed in SEC Form D filings
- Dirk Thye, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Martin S. Brena, Ph.D.DirectorNamed in SEC Form D filings
- Pascal S. KroteeDirectorNamed in SEC Form D filings
Show all 9 people
- Philip S. Low, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Stewart A. Low, Ph.D.Executive OfficerNamed in SEC Form D filings
- William J. Boyle, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingBone Targeted Treatment In Osteogenesis ImperfectaUSPTOApplication 63299746
Related companies, and why
- EnBiotix, Inc.Similar federal contract value in Biotech · null in contracts
- MIMIVAX, LLCSimilar federal contract value in Biotech · null in contracts
- T3D Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Everest Biolabs, Inc.Similar federal contract value in Biotech · null in contracts
- SIGNUM BIOSCIENCESSimilar federal contract value in Biotech · null in contracts
- OMVAX, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .